IL103160A - Pharmaceuticals Containing 1,2,4 [Triazolo] -A] 4,3 Quinoxaline-4-Ones and 1,4Dions for the treatment of indications related to neurotransmitter overactivity - Google Patents

Pharmaceuticals Containing 1,2,4 [Triazolo] -A] 4,3 Quinoxaline-4-Ones and 1,4Dions for the treatment of indications related to neurotransmitter overactivity

Info

Publication number: IL103160A
Authority: IL; Israel
Prior art keywords: compound; quinoxaline; dione; triazolo; formula
Prior art date: 1991-09-20

Application number

IL10316092A

Other languages

English (en)

Hebrew (he)

Other versions

IL103160A0 (en

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-09-20

Filing date

1992-09-14

Publication date

1999-08-17

1992-09-14 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

1993-02-21 Publication of IL103160A0 publication Critical patent/IL103160A0/xx

1999-08-17 Publication of IL103160A publication Critical patent/IL103160A/en

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 105
230000002964 excitative effect Effects 0.000 title claims abstract description 13
208000013403 hyperactivity Diseases 0.000 title claims abstract description 10
239000002858 neurotransmitter agent Substances 0.000 title claims abstract description 10
239000008194 pharmaceutical composition Substances 0.000 title claims description 12
238000002360 preparation method Methods 0.000 title description 3
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 76
239000001257 hydrogen Substances 0.000 claims abstract description 16
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 11
238000000034 method Methods 0.000 claims abstract description 11
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 8
229910052736 halogen Inorganic materials 0.000 claims abstract description 7
150000002367 halogens Chemical class 0.000 claims abstract description 5
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims abstract 2
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 11
-1 quinoxaline compound Chemical class 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 11
230000003042 antagnostic effect Effects 0.000 claims description 6
230000003301 hydrolyzing effect Effects 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 5
201000006474 Brain Ischemia Diseases 0.000 claims description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
230000002152 alkylating effect Effects 0.000 claims description 4
238000006392 deoxygenation reaction Methods 0.000 claims description 4
206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
208000027089 Parkinsonian disease Diseases 0.000 claims description 3
206010034010 Parkinsonism Diseases 0.000 claims description 3
206010008118 cerebral infarction Diseases 0.000 claims description 3
VFTOHJFKIJLYKN-UHFFFAOYSA-N 7-nitro-9h-fluoren-2-ol Chemical group [O-][N+](=O)C1=CC=C2C3=CC=C(O)C=C3CC2=C1 VFTOHJFKIJLYKN-UHFFFAOYSA-N 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
150000003252 quinoxalines Chemical class 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 2
238000007363 ring formation reaction Methods 0.000 claims 2
MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 claims 1
101100134925 Gallus gallus COR6 gene Proteins 0.000 claims 1
YTBODSVQSOILIJ-UHFFFAOYSA-N N-[5-[7-[2-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]ethoxy]-1,3-dihydro-2-benzofuran-5-yl]-2-methoxypyridin-3-yl]methanesulfonamide Chemical compound COc1ncc(cc1NS(C)(=O)=O)-c1cc2COCc2c(OCCN2CCC(CC2)C(C)(C)O)c1 YTBODSVQSOILIJ-UHFFFAOYSA-N 0.000 claims 1
CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 28
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
150000002431 hydrogen Chemical class 0.000 abstract 2
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
125000001567 quinoxalinyl group Chemical class N1=C(C=NC2=CC=CC=C12)* 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
238000005160 1H NMR spectroscopy Methods 0.000 description 22
239000000243 solution Substances 0.000 description 22
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
239000002244 precipitate Substances 0.000 description 15
238000012360 testing method Methods 0.000 description 13
JSFLFNPZGIDUBV-UHFFFAOYSA-N 3-(2-amino-3-hydroxy-5-methyl-3h-1,2-oxazol-4-yl)propanoic acid Chemical compound CC1=C(CCC(O)=O)C(O)N(N)O1 JSFLFNPZGIDUBV-UHFFFAOYSA-N 0.000 description 11
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
229960000583 acetic acid Drugs 0.000 description 10
239000005557 antagonist Substances 0.000 description 10
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
229910052783 alkali metal Inorganic materials 0.000 description 9
238000003756 stirring Methods 0.000 description 9
DWHVZCLBMTZRQM-UHFFFAOYSA-N 2H-pyrazolo[4,3-b]quinoxalin-3-amine Chemical compound C1=CC=CC2=NC3=C(N)NN=C3N=C21 DWHVZCLBMTZRQM-UHFFFAOYSA-N 0.000 description 8
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 7
ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 7
235000019439 ethyl acetate Nutrition 0.000 description 7
239000007787 solid Substances 0.000 description 7
102000003678 AMPA Receptors Human genes 0.000 description 6
108090000078 AMPA Receptors Proteins 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
ZTPNVPPLIDWEGE-UHFFFAOYSA-N P.S.S Chemical compound P.S.S ZTPNVPPLIDWEGE-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
150000001340 alkali metals Chemical class 0.000 description 6
238000009739 binding Methods 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
230000027455 binding Effects 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
239000012362 glacial acetic acid Substances 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
102000018899 Glutamate Receptors Human genes 0.000 description 4
108010027915 Glutamate Receptors Proteins 0.000 description 4
102000000079 Kainic Acid Receptors Human genes 0.000 description 4
108010069902 Kainic Acid Receptors Proteins 0.000 description 4
239000000872 buffer Substances 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
238000004440 column chromatography Methods 0.000 description 4
238000001816 cooling Methods 0.000 description 4
239000012043 crude product Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
229960002989 glutamic acid Drugs 0.000 description 4
VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
230000004044 response Effects 0.000 description 4
210000001525 retina Anatomy 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
239000002904 solvent Substances 0.000 description 4
230000007480 spreading Effects 0.000 description 4
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
FYOBNBAJDBDNSU-UHFFFAOYSA-N (3-chloro-6-nitroquinoxalin-2-yl)hydrazine Chemical compound C1=C([N+]([O-])=O)C=C2N=C(Cl)C(NN)=NC2=C1 FYOBNBAJDBDNSU-UHFFFAOYSA-N 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 3
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000000556 agonist Substances 0.000 description 3
VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
HERPVHLYIHBEFW-ZETCQYMHSA-N diethyl (2s)-2-aminopentanedioate Chemical compound CCOC(=O)CC[C@H](N)C(=O)OCC HERPVHLYIHBEFW-ZETCQYMHSA-N 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
230000002461 excitatory amino acid Effects 0.000 description 3
239000003257 excitatory amino acid Substances 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
229950006874 kainic acid Drugs 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
210000000278 spinal cord Anatomy 0.000 description 3
QEGKMGZYSYDNJL-UHFFFAOYSA-N (3-methoxy-7-nitroquinoxalin-2-yl)hydrazine Chemical compound C1=C([N+]([O-])=O)C=C2N=C(NN)C(OC)=NC2=C1 QEGKMGZYSYDNJL-UHFFFAOYSA-N 0.000 description 2
NWTMXMUENRSUFI-UHFFFAOYSA-N 1,4-dioxo-2,5-dihydro-[1,2,4]triazolo[4,3-a]quinoxaline-7-carbonitrile Chemical compound C1=C(C#N)C=C2NC(=O)C3=NNC(=O)N3C2=C1 NWTMXMUENRSUFI-UHFFFAOYSA-N 0.000 description 2
JJTQVWHSMBWEJX-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)quinoxaline Chemical compound N1=C(Cl)C(Cl)=NC2=CC(C(F)(F)F)=CC=C21 JJTQVWHSMBWEJX-UHFFFAOYSA-N 0.000 description 2
SFJCUOAQTGDBPO-UHFFFAOYSA-N 2,3-dichloro-6-nitroquinoxaline Chemical compound N1=C(Cl)C(Cl)=NC2=CC([N+](=O)[O-])=CC=C21 SFJCUOAQTGDBPO-UHFFFAOYSA-N 0.000 description 2
SPSSDDOTEZKOOV-UHFFFAOYSA-N 2,3-dichloroquinoxaline Chemical compound C1=CC=C2N=C(Cl)C(Cl)=NC2=C1 SPSSDDOTEZKOOV-UHFFFAOYSA-N 0.000 description 2
QQWXZJWBGMGQTQ-UHFFFAOYSA-N 3,6,7-trichloro-1h-quinoxalin-2-one Chemical compound N1=C(Cl)C(=O)NC2=C1C=C(Cl)C(Cl)=C2 QQWXZJWBGMGQTQ-UHFFFAOYSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
241000976983 Anoxia Species 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
208000023105 Huntington disease Diseases 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000002740 Muscle Rigidity Diseases 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
229940024606 amino acid Drugs 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000036592 analgesia Effects 0.000 description 2
230000007953 anoxia Effects 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
229960005261 aspartic acid Drugs 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
239000003610 charcoal Substances 0.000 description 2
ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
230000003226 decolorizating effect Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
230000000857 drug effect Effects 0.000 description 2
239000003480 eluent Substances 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
JRAYAVYSZYZZKB-UHFFFAOYSA-N ethyl n-[(6,7-dichloro-3-oxo-4h-quinoxalin-2-yl)amino]carbamate Chemical compound ClC1=C(Cl)C=C2NC(=O)C(NNC(=O)OCC)=NC2=C1 JRAYAVYSZYZZKB-UHFFFAOYSA-N 0.000 description 2
VYSYZMNJHYOXGN-UHFFFAOYSA-N ethyl n-aminocarbamate Chemical compound CCOC(=O)NN VYSYZMNJHYOXGN-UHFFFAOYSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
210000003128 head Anatomy 0.000 description 2
150000002391 heterocyclic compounds Chemical class 0.000 description 2
230000002218 hypoglycaemic effect Effects 0.000 description 2
239000012535 impurity Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000001722 neurochemical effect Effects 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
239000000047 product Substances 0.000 description 2
208000020016 psychiatric disease Diseases 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000010288 sodium nitrite Nutrition 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
230000008733 trauma Effects 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
IRJCBFDCFXCWGO-SCSAIBSYSA-N (2r)-2-azaniumyl-2-(3-oxo-1,2-oxazol-5-yl)acetate Chemical compound [O-]C(=O)[C@H]([NH3+])C1=CC(=O)NO1 IRJCBFDCFXCWGO-SCSAIBSYSA-N 0.000 description 1
PTLWNCBCBZZBJI-RFZPGFLSSA-N (2r,3r)-piperidine-2,3-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN[C@H]1C(O)=O PTLWNCBCBZZBJI-RFZPGFLSSA-N 0.000 description 1
UMIBNTAMBAHQPV-UHFFFAOYSA-N (3,7-dichloroquinoxalin-2-yl)hydrazine Chemical compound ClC1=CC=C2N=C(Cl)C(NN)=NC2=C1 UMIBNTAMBAHQPV-UHFFFAOYSA-N 0.000 description 1
UVCAWLYCXOGQFU-UHFFFAOYSA-N (6-chloro-3-methoxyquinoxalin-2-yl)hydrazine Chemical compound ClC1=CC=C2N=C(NN)C(OC)=NC2=C1 UVCAWLYCXOGQFU-UHFFFAOYSA-N 0.000 description 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical class OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
ABJFBJGGLJVMAQ-UHFFFAOYSA-N 1,4-dihydroquinoxaline-2,3-dione Chemical class C1=CC=C2NC(=O)C(=O)NC2=C1 ABJFBJGGLJVMAQ-UHFFFAOYSA-N 0.000 description 1
RZXLQUYIHHMTBC-UHFFFAOYSA-N 1-propyl-7-(trifluoromethyl)-5h-[1,2,4]triazolo[4,3-a]quinoxalin-4-one Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=NN=C(CCC)N3C2=C1 RZXLQUYIHHMTBC-UHFFFAOYSA-N 0.000 description 1
VPHWXQSGCPAURB-UHFFFAOYSA-N 2,5-dihydro-[1,2,4]triazolo[4,3-a]quinoxaline-1,4-dione Chemical compound C1=CC=C2N3C(O)=NN=C3C(O)=NC2=C1 VPHWXQSGCPAURB-UHFFFAOYSA-N 0.000 description 1
IRUPUWIXKXPULC-UHFFFAOYSA-N 3-chloro-2-methoxy-6-nitroquinoxaline Chemical compound C1=C([N+]([O-])=O)C=C2N=C(Cl)C(OC)=NC2=C1 IRUPUWIXKXPULC-UHFFFAOYSA-N 0.000 description 1
RANSVFRDBNQZOX-UHFFFAOYSA-N 4,8-dichloro-2h-[1,2,4]triazolo[4,3-a]quinoxalin-1-one Chemical compound N1=C(Cl)C2=NNC(=O)N2C2=CC(Cl)=CC=C21 RANSVFRDBNQZOX-UHFFFAOYSA-N 0.000 description 1
HTPXAWZKVSHPKT-UHFFFAOYSA-N 4-hydroxy-1h-quinoxaline-2,3-dione Chemical compound C1=CC=C2NC(=O)C(=O)N(O)C2=C1 HTPXAWZKVSHPKT-UHFFFAOYSA-N 0.000 description 1
VOROEQBFPPIACJ-UHFFFAOYSA-N 5-Phosphononorvaline Chemical compound OC(=O)C(N)CCCP(O)(O)=O VOROEQBFPPIACJ-UHFFFAOYSA-N 0.000 description 1
AVBSIKMUAFYZAV-UHFFFAOYSA-N 6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C(Cl)C(Cl)=C2 AVBSIKMUAFYZAV-UHFFFAOYSA-N 0.000 description 1
WSOFUOYCKQKGRV-UHFFFAOYSA-N 6-chloro-2,3-dioxo-4-phenylmethoxy-1h-quinoxaline-5-carbonitrile Chemical compound C12=C(C#N)C(Cl)=CC=C2NC(=O)C(=O)N1OCC1=CC=CC=C1 WSOFUOYCKQKGRV-UHFFFAOYSA-N 0.000 description 1
ALSGWYZDRADWSN-UHFFFAOYSA-N 6-chloro-4-hydroxy-2,3-dioxo-1h-quinoxaline-5-carbonitrile Chemical compound ClC1=CC=C2NC(=O)C(=O)N(O)C2=C1C#N ALSGWYZDRADWSN-UHFFFAOYSA-N 0.000 description 1
AQSHFEIOKPUEAU-UHFFFAOYSA-N 6-nitro-8-(trifluoromethyl)-2,5-dihydro-[1,2,4]triazolo[4,3-a]quinoxaline-1,4-dione Chemical compound N1C(=O)C2=NNC(=O)N2C2=C1C([N+](=O)[O-])=CC(C(F)(F)F)=C2 AQSHFEIOKPUEAU-UHFFFAOYSA-N 0.000 description 1
MBIWQPMWWCZRBS-UHFFFAOYSA-N 7,8-dichloro-2,5-dihydro-[1,2,4]triazolo[4,3-a]quinoxaline-1,4-dione Chemical compound ClC=1C=C2NC(C=3N(C2=CC1Cl)C(NN3)=O)=O MBIWQPMWWCZRBS-UHFFFAOYSA-N 0.000 description 1
GTSWAIWOKMWHNO-UHFFFAOYSA-N 7-(trifluoromethyl)-2,5-dihydro-[1,2,4]triazolo[4,3-a]quinoxaline-1,4-dione Chemical compound N1C(=O)C2=NNC(=O)N2C2=CC=C(C(F)(F)F)C=C21 GTSWAIWOKMWHNO-UHFFFAOYSA-N 0.000 description 1
FJKNRDNQDWPAAP-UHFFFAOYSA-N 7-chloro-1,4-dioxo-2,5-dihydro-[1,2,4]triazolo[4,3-a]quinoxaline-6-carbonitrile Chemical compound N1C(=O)C2=NNC(=O)N2C2=CC=C(Cl)C(C#N)=C12 FJKNRDNQDWPAAP-UHFFFAOYSA-N 0.000 description 1
BINPKQLYTWUFRZ-UHFFFAOYSA-N 7-chloro-2,5-dihydro-[1,2,4]triazolo[4,3-a]quinoxaline-1,4-dione Chemical compound N1C(=O)C2=NNC(=O)N2C2=CC=C(Cl)C=C21 BINPKQLYTWUFRZ-UHFFFAOYSA-N 0.000 description 1
KVJVNBXSLPXECR-UHFFFAOYSA-N 8-(trifluoromethyl)-2,5-dihydro-[1,2,4]triazolo[4,3-a]quinoxaline-1,4-dione Chemical compound N1C(=O)C2=NNC(=O)N2C2=CC(C(F)(F)F)=CC=C21 KVJVNBXSLPXECR-UHFFFAOYSA-N 0.000 description 1
DQJQCRRVQSQDLT-UHFFFAOYSA-N 8-chloro-2,5-dihydro-[1,2,4]triazolo[4,3-a]quinoxaline-1,4-dione Chemical compound N1C(=O)C2=NNC(=O)N2C2=CC(Cl)=CC=C21 DQJQCRRVQSQDLT-UHFFFAOYSA-N 0.000 description 1
SUKFLVYCCJYRBZ-UHFFFAOYSA-N 8-chloro-7-nitro-2,5-dihydro-[1,2,4]triazolo[4,3-a]quinoxaline-1,4-dione Chemical compound N1C(=O)C2=NNC(=O)N2C2=C1C=C([N+](=O)[O-])C(Cl)=C2 SUKFLVYCCJYRBZ-UHFFFAOYSA-N 0.000 description 1
IDGDLAJNDUAMHK-UHFFFAOYSA-N 8-nitro-2,5-dihydro-[1,2,4]triazolo[4,3-a]quinoxaline-1,4-dione Chemical compound N1C(=O)C2=NNC(=O)N2C2=CC([N+](=O)[O-])=CC=C21 IDGDLAJNDUAMHK-UHFFFAOYSA-N 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
102000015404 Amino Acid Receptors Human genes 0.000 description 1
108010025177 Amino Acid Receptors Proteins 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
208000002381 Brain Hypoxia Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
OYIFNHCXNCRBQI-SCSAIBSYSA-N D-2-aminoadipic acid Chemical compound OC(=O)[C@H](N)CCCC(O)=O OYIFNHCXNCRBQI-SCSAIBSYSA-N 0.000 description 1
WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
229930182847 D-glutamic acid Natural products 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
QQWKPDFCCSAGMI-UHFFFAOYSA-N FC(C1=NN=C2N1C1=CC=C(C=C1NC2=O)[N+](=O)[O-])(F)F Chemical compound FC(C1=NN=C2N1C1=CC=C(C=C1NC2=O)[N+](=O)[O-])(F)F QQWKPDFCCSAGMI-UHFFFAOYSA-N 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
241000699694 Gerbillinae Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
IRJCBFDCFXCWGO-UHFFFAOYSA-N Ibotenic acid Natural products OC(=O)C(N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
VBOQYPQEPHKASR-VKHMYHEASA-N L-homocysteic acid Chemical compound OC(=O)[C@@H](N)CCS(O)(=O)=O VBOQYPQEPHKASR-VKHMYHEASA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
PYKZCFAOBBKPRF-UHFFFAOYSA-N [3-chloro-6-(trifluoromethyl)quinoxalin-2-yl]hydrazine Chemical class C1=C(C(F)(F)F)C=C2N=C(Cl)C(NN)=NC2=C1 PYKZCFAOBBKPRF-UHFFFAOYSA-N 0.000 description 1
XWCVQWMPEUTPEV-UHFFFAOYSA-N [3-chloro-7-(trifluoromethyl)quinoxalin-2-yl]hydrazine Chemical compound FC(F)(F)C1=CC=C2N=C(Cl)C(NN)=NC2=C1 XWCVQWMPEUTPEV-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
230000009460 calcium influx Effects 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
229960003280 cupric chloride Drugs 0.000 description 1
MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940049906 glutamate Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000016273 neuron death Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
BYMZQQLCZDLNKW-UHFFFAOYSA-N nickel(2+);tetracyanide Chemical compound [Ni+2].N#[C-].N#[C-].N#[C-].N#[C-] BYMZQQLCZDLNKW-UHFFFAOYSA-N 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000004323 potassium nitrate Substances 0.000 description 1
235000010333 potassium nitrate Nutrition 0.000 description 1
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

IL10316092A 1991-09-20 1992-09-14 Pharmaceuticals Containing 1,2,4 [Triazolo] -A] 4,3 Quinoxaline-4-Ones and 1,4Dions for the treatment of indications related to neurotransmitter overactivity IL103160A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK911624A DK162491D0 (da)	1991-09-20	1991-09-20	Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne

Publications (2)

Publication Number	Publication Date
IL103160A0 IL103160A0 (en)	1993-02-21
IL103160A true IL103160A (en)	1999-08-17

Family

ID=8106648

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10316092A IL103160A (en)	1991-09-20	1992-09-14	Pharmaceuticals Containing 1,2,4 [Triazolo] -A] 4,3 Quinoxaline-4-Ones and 1,4Dions for the treatment of indications related to neurotransmitter overactivity

Country Status (13)

Country	Link
US (1)	US5504085A (fi)
EP (1)	EP0633885A1 (fi)
JP (1)	JPH07501791A (fi)
AU (1)	AU663523B2 (fi)
CA (1)	CA2119579A1 (fi)
DK (1)	DK162491D0 (fi)
FI (1)	FI106719B (fi)
IL (1)	IL103160A (fi)
NO (1)	NO302368B1 (fi)
NZ (1)	NZ244398A (fi)
TW (1)	TW210341B (fi)
WO (1)	WO1993006103A1 (fi)
ZA (1)	ZA927172B (fi)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1041931C (zh) *	1993-05-06	1999-02-03	诺沃-诺迪斯克有限公司	[1,2,4]三唑并[4,3－a]喹喔啉化合物,它们的制备及其应用
EP0750631B1 (en) *	1994-02-14	2000-04-05	Merrell Pharmaceuticals Inc.	Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo(c)azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace
FR2717812B1 (fr) *	1994-03-28	1996-05-10	Rhone Poulenc Rorer Sa	Indeno[1,2-e]pyrazine-4-ones, leur préparation et les médicaments les contenant.
FR2717813B1 (fr) *	1994-03-28	1996-05-10	Rhone Poulenc Rorer Sa	Dérivés d'imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant .
FR2717805B1 (fr) *	1994-03-28	1996-05-10	Rhone Poulenc Rorer Sa	Dérivés de 5H-indeno[1,2-b]pyrazine-2,3-dione, leur préparation et les médicaments les contenant .
FR2717814B1 (fr) *	1994-03-28	1996-04-26	Rhone Poulenc Rorer Sa	Dérivés de 1,2,4-triazolo(4,3-a)pyrazine-4-one, leur préparation et les médicaments les contenant.
FR2722789B1 (fr) *	1994-07-20	1996-08-23	Rhone Poulenc Rorer Sa	Derives d'acide imidazo (1,2-a)indeno(1,2-e) pyrazine-2-carboxylique, leur preparation et les medicaments les contenant
ATE190616T1 (de) *	1994-09-16	2000-04-15	Novo Nordisk As	(1,2,4)triazolo(4,3-a)chinoxylinonderivate, ihre darstellung und verwendung als antagonisten von ampa-rezeptoren
HUT76802A (en) *	1994-09-16	1997-11-28	Novo Nordisk As	[1,2,4]triazolo[4,3-a]quinoxalinone derivatives,process for their preparation and pharmaceutical compositions containing them
US5679680A (en) *	1995-02-16	1997-10-21	Warner-Lambert Company	α-substituted hydrazides having calpain inhibitory activity
US5958926A (en)	1996-11-01	1999-09-28	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en) *	1996-11-01	2001-06-19	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
IL125950A0 (en) *	1997-09-05	1999-04-11	Pfizer Prod Inc	Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US20040152694A1 (en) *	2003-02-04	2004-08-05	Istvan Kurucz	Methods and compositions for treating inflammatory disorders of the airways
EP2103613B1 (en) *	2006-12-13	2016-02-17	ASKA Pharmaceutical Co., Ltd.	Quinoxaline derivative
EP2338492A1 (en)	2009-12-24	2011-06-29	Universidad del Pais Vasco	Methods and compositions for the treatment of alzheimer
CN103097393B (zh) *	2010-09-07	2015-09-16	安斯泰来制药株式会社	喹喔啉化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4400382A (en) *	1980-05-09	1983-08-23	Usv Pharmaceutical Corporation	Thiazoloquinoxalin-1,4-diones for treating allergy
US4354027A (en) *	1980-05-19	1982-10-12	Usv Pharmaceutical Corporation	Triazoloquinoxalin-4-ones
US4623725A (en) *	1982-10-18	1986-11-18	Pfizer Inc.	[1,2,4]Triazolo[4,3-a]quinoxaline-4-amine derivatives
US4780464A (en) *	1986-12-08	1988-10-25	Warner-Lambert Company	(1,2,4)triazolo(4,3-a)quinoxaline-4-amines
DK160941C (da) *	1988-06-28	1991-10-21	Novo Nordisk As	Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar
US4975430A (en) *	1989-06-16	1990-12-04	The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University	CNQX and its analogs as therapeutics for degenerative neural diseases
JP2550456B2 (ja) *	1990-11-06	1996-11-06	山之内製薬株式会社	縮合ピラジン誘導体
PT101004B (pt) *	1991-10-26	1999-10-29	Schering Ag	Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem
FR2690160A1 (fr) *	1992-04-15	1993-10-22	Rhone Poulenc Rorer Sa	Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant.

1991
- 1991-09-20 DK DK911624A patent/DK162491D0/da not_active IP Right Cessation
1992
- 1992-09-09 WO PCT/DK1992/000271 patent/WO1993006103A1/en not_active Application Discontinuation
- 1992-09-09 JP JP5505705A patent/JPH07501791A/ja active Pending
- 1992-09-09 CA CA002119579A patent/CA2119579A1/en not_active Abandoned
- 1992-09-09 EP EP92920312A patent/EP0633885A1/en not_active Withdrawn
- 1992-09-09 AU AU26600/92A patent/AU663523B2/en not_active Ceased
- 1992-09-14 IL IL10316092A patent/IL103160A/en not_active IP Right Cessation
- 1992-09-15 TW TW081107243A patent/TW210341B/zh active
- 1992-09-18 ZA ZA927172A patent/ZA927172B/xx unknown
- 1992-09-18 NZ NZ244398A patent/NZ244398A/en unknown
1994
- 1994-03-18 FI FI941287A patent/FI106719B/fi active
- 1994-03-18 NO NO940989A patent/NO302368B1/no not_active IP Right Cessation
- 1994-08-03 US US08/285,598 patent/US5504085A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO1993006103A1 (en)	1993-04-01
ZA927172B (en)	1993-03-24
NO940989L (no)	1994-03-18
FI941287A0 (fi)	1994-03-18
AU2660092A (en)	1993-04-27
TW210341B (fi)	1993-08-01
DK162491D0 (da)	1991-09-20
CA2119579A1 (en)	1993-04-01
FI106719B (fi)	2001-03-30
EP0633885A1 (en)	1995-01-18
IL103160A0 (en)	1993-02-21
FI941287L (fi)	1994-03-18
NO940989D0 (no)	1994-03-18
AU663523B2 (en)	1995-10-12
NO302368B1 (no)	1998-02-23
JPH07501791A (ja)	1995-02-23
NZ244398A (en)	1995-02-24
US5504085A (en)	1996-04-02

Publication	Publication Date	Title
US5504085A (en)	1996-04-02	Triazolo quinoxalines and their preparation and use
AU652560B2 (en)	1994-09-01	Quinoxaline compounds and their preparation and use
US5559106A (en)	1996-09-24	Heterocyclic compounds, their use and preparation
KR100304177B1 (ko)	2001-11-22	(1,2,4)트리아졸로(4,3-a)퀴녹살린화합물,이의제조방법및이를함유하는약제학적조성물_
US5741785A (en)	1998-04-21	Heterocyclic compounds, their preparation and use
EP0511152A2 (en)	1992-10-28	Quinoxaline compounds, their preparation and use
EP0783504B1 (en)	2000-03-15	[1,2,4]TRIAZOLO[4,3-a]QUINOXALINONE DERIVATIVES, THEIR PREPARATION AND USE AS ANTAGONISTS OF AMPA-RECEPTORS
AU694554B2 (en)	1998-07-23	{1,2,4}triazolo{4,3-a}quinoxalinone derivatives, their preparation and use

Legal Events

Date	Code	Title
1999-12-22	FF	Patent granted
2000-08-13	KB	Patent renewed
2003-06-24	RH1	Patent not in force